Mereo BioPharma Announces Listing Transfer to Nasdaq Capital Market
LONDON, May 05, 2023 (GLOBE NEWSWIRE) — Mereo BioPharma Group plc (NASDAQ:MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that it has received approval from Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) to transfer the listing of its American Depositary Shares (“ADSs”) from the Nasdaq Global Market to the Nasdaq Capital Market. This transfer became effective at the opening of business on May 3, 2023.